Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime PK in Hemodialysis
NCT03634904Unknown
- Sponsor
- CHU de Charleroi
- Start
- Sep 2018
- Primary completion
- Sep 2020
- Modality
- Reversible Covalent Inhibitors
01
Overview
Open-label, single-arm trial of ceftazidime in bacterial infection, sponsored by CHU de Charleroi. Primary endpoint: Trough level at 8 mg/L or 1 x the MIC at 7 days. Status: unknown.
02
Drugs
ceftazidime
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03634904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634904.